PMID- 18676096
OWN - NLM
STAT- MEDLINE
DCOM- 20090303
LR  - 20220330
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 73
IP  - 3
DP  - 2009 Mar 1
TI  - Quality of life of oral cancer patients after low-dose-rate interstitial 
      brachytherapy.
PG  - 772-8
LID - 10.1016/j.ijrobp.2008.05.001 [doi]
AB  - PURPOSE: To assess the quality of life (QOL) of oral cancer patients treated with 
      low-dose-rate interstitial brachytherapy (LDR-BT) alone. METHODS AND MATERIALS: 
      Between June 2005 and July 2006, a total of 56 patients with oral cancer were 
      enrolled in this prospective study. QOL was assessed by means of the core 
      questionnaire and head and neck questionnaire module of the European Organization 
      for Research and Treatment of Cancer (EORTC Quality of Life Questionnaire-Core 30 
      [QLQ-C30] and QLQ Head and Neck 35 [H&N35]). The questionnaires were distributed 
      to the patients before the start of treatment and 3 months, 6 months, and 12 
      months after the start of LDR-BT. RESULTS: It was possible to analyze the results 
      for 20 of the initial 56 patients because they did not experience metastasis or 
      recurrence during this study. No functions or symptoms asked about in the QLQ-C30 
      deteriorated during the first year. The emotional function score steadily and 
      significantly increased. No symptoms in the QLQ-H&N35 significantly deteriorated. 
      The scores for pain, trouble with social eating, and weight loss on the QLQ-H&N35 
      steadily and significantly decreased. Age, gender, and LDR-BT source had no 
      effect on the change in QOL during the first year, but T-stage significantly 
      affected the change in global health status, tumor site affected the changes in 
      swallowing, sensory problems, sticky saliva, and complications affected the 
      changes in pain, swallowing, and mouth opening. CONCLUSIONS: QOL of oral cancer 
      patients treated with LDR-BT is high. However, tumor stage, tumor site, and 
      complications affected the changes in a few functions and symptoms during the 
      first year.
FAU - Yoshimura, Ryo-ichi
AU  - Yoshimura R
AD  - Division of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. 
      ryoshimu@ncc.go.jp
FAU - Shibuya, Hitoshi
AU  - Shibuya H
FAU - Miura, Masahiko
AU  - Miura M
FAU - Watanabe, Hiroshi
AU  - Watanabe H
FAU - Ayukawa, Fumio
AU  - Ayukawa F
FAU - Hayashi, Keiji
AU  - Hayashi K
FAU - Toda, Kazuma
AU  - Toda K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
RN  - 0 (Cesium Radioisotopes)
RN  - 0 (Gold Radioisotopes)
RN  - 0 (Iridium Radioisotopes)
SB  - IM
CIN - Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1285; author reply 1285. PMID: 
      19251103
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brachytherapy/adverse effects/*methods
MH  - Cesium Radioisotopes/therapeutic use
MH  - Deglutition
MH  - Female
MH  - Gold Radioisotopes/therapeutic use
MH  - Humans
MH  - Iridium Radioisotopes/therapeutic use
MH  - Lymphatic Metastasis/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/complications/pathology/*radiotherapy
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Radiotherapy Dosage
MH  - *Surveys and Questionnaires
MH  - Tongue Neoplasms/complications/pathology/radiotherapy
EDAT- 2008/08/05 09:00
MHDA- 2009/03/04 09:00
CRDT- 2008/08/05 09:00
PHST- 2008/03/02 00:00 [received]
PHST- 2008/05/02 00:00 [revised]
PHST- 2008/05/02 00:00 [accepted]
PHST- 2008/08/05 09:00 [pubmed]
PHST- 2009/03/04 09:00 [medline]
PHST- 2008/08/05 09:00 [entrez]
AID - S0360-3016(08)00780-3 [pii]
AID - 10.1016/j.ijrobp.2008.05.001 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):772-8. doi: 
      10.1016/j.ijrobp.2008.05.001.